# LINCOLN PHARMA 1-Promotors holding 32.36%( low holding- negative). 2-MCAP 300 Cr , BV 148 , Last 3 yrs sales growth - 2.91%, ROE last 3 yrs 18% , ROCE Last 3 yrs around 20 increase in debator days.
3-Sales down from 400 Cr in 2016 to 366 Cr in 2019 but profit increased from 24 to 51 Cr at same time with OPM 10 to 18% because of discontinuation of low margin contract manufacturing business for third parties and launch of new branded products and new drug delivery systems
4-Debt 37 Cr. 5-It has 3 subsidiaries 1- Zullinc health care ( NP 10 lac in 2018-19) 2 - Lincoln Parenteral - NP around 2 Cr fy 19 ( now merged ) 3- Savebux (np 2 lac in fy 19 )
6-Lincoln has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. and is awarded five patents
7-Company has filled 20 plus patent applications and awarded 5 patents 8 -Export business has shown remarkable growth in the last few years. Exports have increased to 61% of total sales in FY20 from 11% of total sales in FY11.
Company has almost doubled the export turnover in FY20 as compared to FY18. Export of the company stood at Rs. 227 crore in FY 20 as compared to Rs. 197 crore in FY 19, a growth of 15% Y-O-Y.
9-received the European Union (EU) GMP certification from Germany FDA for its manufacturing facility located at Khatraj in Gujarat, which allow the company to market its products in all the 27 member countries of EU and also give access to the European Economic Area (EEA)
10-Recently awarded a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray)and Company is applying for global patent ,it is alternative to Diclofenac suppository.
The market for Diclofenac Rectal Suppository is estimated at ₹20 crore in India with a growth of 16 per cent per annum
Diclofenac Rectal Spray is highly effective in patients suffering from pre and postoperative pain, gynaecological surgery and musculoskeletal disorders such as muscular pain, pain associated with arthritis, acute pain in renal colic and mild body ache.”
11-During FY17-18, the company launched some novel products including a delivery system for accurate 25mg delivery of micronized progesterone/spray, ( PROLIN )which releases the formulation in a mist form (spray) and is, thus, better than tablets, capsules and injections.
It also launched, a paracetamol 1,000mg programmed release tablet which is more hepato-friendly, an injection for relief from tinnitus, a low-viscosity formulation for malaria, and a meter dose pump ( Domi up spray)to delivers 2mg of Ondansetron Hydrochloride
Which is more convenient for patients compared to an injectable (Domi Up Spray). Ondansetron oral spray, used for treatment of nausea and vomiting caused by surgery or cancer drugs.
12-Regular Dividend by Company
13In lock down because of logistics problem I expect poor result and price correction and which may be a opportunity to accumulate for long term and I expect company to give investor Presentattions and Concall for better understanding of business
13In lock down because of logistics problem I expect poor result and price correction and which may be a opportunity to accumulate for long term and I expect company to give investor Presentattions and Concall for better understanding of business
@threadreaderapp Unroll
